Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma

Future Oncol. 2019 Feb;15(4):439-449. doi: 10.2217/fon-2018-0269. Epub 2019 Jan 8.

Abstract

Whether to submit to transarterial chemoembolization (TACE) or hepatic resection (HR) patients with hepatocellular carcinoma (HCC) is still a debated issue. We conducted a systematic review to critically analyze what evidence supports the use of TACE, in a specific clinical condition that can define HCC as 'intermediate'. In addition, we analyzed literature regarding the comparison between TACE and HR. Direct comparisons, between HR and TACE, strongly support the adoption of surgery for patients with large or multinodular HCCs since, albeit 'nonideal' surgical candidates, these patients can still obtain a survival benefit. Multidisciplinary teams can mitigate the different decision-making approach of surgeons and hepatologists with the aim of obtaining the best quality of care.

Keywords: decision-making; hepatic resection; hepatocellular carcinoma; survival; systematic review; transarterial chemoembolization; transarterial embolization.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Animals
  • Carcinoma, Hepatocellular / mortality
  • Carcinoma, Hepatocellular / pathology
  • Carcinoma, Hepatocellular / therapy*
  • Chemoembolization, Therapeutic* / methods
  • Clinical Decision-Making
  • Combined Modality Therapy
  • Disease Management
  • Hepatectomy* / methods
  • Humans
  • Liver Neoplasms / mortality
  • Liver Neoplasms / pathology
  • Liver Neoplasms / therapy*
  • Neoplasm Staging
  • Treatment Outcome